2026 Outlook The FY 2026 guidance incorporates the impact from the raw material classification change impacting Centrum OTC-registered products in China and an expected impact of the acceleration of our new go-to-market model in Brazil. (See below). As a result, the Group now expects for FY 2026: Organic revenue growth to be around 2.5% High-single digit adjusted operating profit growth at constant currency Net interest c.£255m; Adjusted effective tax rate c.24.5%

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.